Angiotensin II receptor / Thiazide diuretic

Class

Antihypertensive fixed-dose combination (class-level disclosure)

Notes

Created for N0877 — components disclosed only at class level (https://www.pharmaceutical-technology.com/data-insights/n-0877-eurofarma-laboratorios-idiopathic-essential-hypertension-likelihood-of-approval/); double-dummy design vs Benicar HCT (NCT06608472) implies olmesartan/HCTZ but that is not stated verbatim — researched 2026-08-08

This mechanism combines two complementary blood pressure–lowering strategies in a single fixed-dose product: an angiotensin II receptor blocker (ARB) and a thiazide diuretic. The ARB component blocks the angiotensin II type 1 (AT1) receptor, preventing the hormone angiotensin II from causing blood vessel constriction and stimulating aldosterone release, both of which raise blood pressure. The thiazide component acts on the kidney, reducing reabsorption of sodium and chloride in the distal nephron, which increases urinary salt and water loss and lowers circulating blood volume. Used together, the two agents lower blood pressure through independent pathways—vascular tone and fluid volume—producing an additive effect that is often greater than either drug alone, while also blunting a physiological counter-response: thiazides tend to activate the renin-angiotensin system, an effect the ARB directly opposes. This class of fixed-dose combination is used broadly in essential hypertension, particularly when blood pressure is not adequately controlled by a single agent, and combining mechanisms in one formulation can also simplify dosing schedules for patients who require multiple antihypertensive medications.